Biomarin, biotech américaine pour les maladies rares

depuis quelques jours, elle n'arrete pas de monter. Je la trouve très intéressante.


BioMarin Pharmaceutical Inc.'s Q3 Revenue Spikes 21% YoY (BMRN)
Written on Thu, 10/28/2010 - 4:33pm
By Chip Brian
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported a 21% year-over-year boost to its Q3 revenue at $97.8 million.
Net product revenue rose 23.2% from the year-ago period to $96.6 million.
The company reported GAPP net income of $217.3 million, or $1.68 per share, up from $6.6 million, or $0.07 per share in the year-ago period.
Non-GAAP net income was $6.0 million, or $0.06 per share, down from $15.5 million, or $0.14 per share in the year-ago period.
"In the third quarter, we saw strong commercial performance, despite being a seasonally weaker quarter," said CEO Jean-Jacques Bienaime. "During the quarter, based upon, among other things, our expectations to generate taxable income for the foreseeable future, we reversed most of our deferred tax asset valuation allowance which resulted in a one-time credit totaling $223.1 million. Our pipeline has advanced tremendously over the last few months as highlighted at our recent R&D Day, and we are committed to investing in advancing the pipeline over the next two years to drive future growth. We look forward to keeping you updated on the many clinical milestones expected in the coming year."
BioMarin Pharmaceutical has a potential upside of 4.1% based on a current price of $24.62 and an average consensus analyst price target of $25.64.
BioMarin Pharmaceutical is currently above its 50-day moving average (MA) of $22.06 and above its 200-day of $21.23.
In the last five trading sessions, the 50-day MA has climbed 1.6% while the 200-day MA has risen 0.48%.
BioMarin Pharmaceutical develops and commercializes therapeutic enzyme products. The Company has applied its proprietary enzyme technology to develop products for lysosomal storage diseases and for the treatment of serious burns.
BioMarin's subsidiary provides analytical and diagnostic products and services in the area of carbohydrate biology.